Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study

Fig. 1

Patient disposition. Two patients (one in the BGF MDI group and one in the BFF MDI group) participated in multiple sponsor-led studies and were excluded from all analysis populations. BFF Budesonide/formoterol fumarate, BGF Budesonide/glycopyrrolate/formoterol fumarate, BMD Bone mineral density, GFF Glycopyrrolate/formoterol fumarate, MDI Metered dose inhaler

Back to article page